FDA Announces More Compounding Pharmacy Recalls

Article

FDA inspections reveal possible inaccurate sterility testing.

FDA inspections of compounding pharmacies have revealed that results of some sterility testing by third-party laboratories may be inaccurate, causing potential risk to patients. University Compounding Pharmacy is voluntarily recalling products, including Testosterone Cypionate (Sesame Oil), Testosterone Cypionate/Testosterone Proprionate, and PGE-1 NS, for injection, to the consumer level. The recall is a result of FDA inspections of methods used by an independent third-party laboratory to assess sterility. FDA believes the sterility test results may not be reliable and there may be microbial contamination in products intended to be sterile.

Last week, FDA announced a voluntary recall of products from Medaus Pharmacy, including sterile compounded consumer products, due to inability to confirm that the quality control testing performed by an independent, third-party laboratory was conducted in a manner consistent with standards.

Source: FDA.gov

 

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes